Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Fosun Pharma and MAIA Pharmaceuticals Jointly Announce the Successful Commercialization of Only FDA Approved 20ml Sodium Phenylacetate and Sodium Benzoate (SPSB) Liquid Product 2022-09-26 22:13
Bioheng Biotech Announces Publication of Impressive Results with CD7-targeted allogeneic CAR-T cell therapy for Relapsed or Refractory T Cell Malignancies 2022-09-26 21:00
PharmAbcine to Participate in BIO-Europe 2022 2022-09-26 20:00
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility 2022-09-26 20:00
CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy 2022-09-26 12:31
111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee 2022-09-23 12:30
RVAC Medicines Initiates First-in-Human Clinical Trials for mRNA COVID-19 Vaccine Candidates 2022-09-22 10:00
Ascentage Pharma Announces Phase I/II Data of Olverembatinib (HQP1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-in-Class Potential 2022-09-21 22:49
Charsire's New Drug Aims to Capture Multi-Billion-Dollar Dementia Treatment Market 2022-09-21 20:00
Mediaseek's Proprietary Neurofeedback Engine "Alpha Switch" and Its Smartphone Application Mentioned in International Journal 2022-09-21 14:00
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy 2022-09-20 19:25
New treatment for rare cancer cholangiocarcinoma approved in Australia 2022-09-15 21:00
Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance 2022-09-15 17:07
J INTS BIO, poster presentation of further preclinical data of its Novel Oral 4th Generation EGFR-TKI 'JIN-A02' at the 2022 European Society for Medical Oncology Congress in Paris, France (ESMO 2022) 2022-09-15 14:12
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome 2022-09-13 20:00
First and only TIGIT/TGF-β dual-targeting antibody fusion protein of Akeso demonstrated promise in preclinical results published at ESMO 2022-09-13 14:02
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 2022-09-10 21:00
Redbud raises $10M in series A round as CRO focusing on science-driven clinical development 2022-09-10 05:13
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company 2022-09-09 17:53
Antengene to Present at Upcoming Industry Conferences 2022-09-09 14:43
1 50 51 52 53 54 148